At 7.1% CAGR, the South & Central America Enteral and Parenteral Medical Nutrition Market is projected to be worth US$ 1,377.32 million by 2028, says Business Market Insights

According to Business Market Insights research, the South & Central America enteral and parenteral medical nutrition market was valued at US$ 975.68 million in 2023 and is expected to reach US$ 1,377.32 million by 2028, registering a CAGR of 7.1% from 2023 to 2028. Rise in prevalence of gastrointestinal diseases and increasing cases of malnutrition and premature births are the critical factors attributed to the South & Central America enteral and parenteral medical nutrition market expansion.        

Companies operating in the enteral and parenteral medical nutrition market constantly focus on strategic developments such as collaborations, expansions, agreements, partnerships, and new product launches, which help them improve their sales, expand their geographic reach, and enhance their capacities to cater to a greater than existing customer base. A few of the noteworthy developments in the enteral and parenteral medical nutrition market are mentioned below: In May 2022, Nestle Health Science acquired Puravida, a premium Brazilian nutrition and healthy lifestyle brand. Puravida's products complement Nestle’s portfolio. Vitamins, minerals, and supplements are part of a growing segment of Nestle and with this acquisition, the company has the ability to expand its range of brands in different categories and reach a broader range of consumers and patients with improved reliable, nutritious, and high-quality products. In March 2022, Vygon (a specialist single-use medical devices group) acquired Macatt Medica (a distribution company located in Peru). Macatt Medica distributes most of Vygon’s products in Peru, including a range of enteral nutrition products. With the acquisition, Macatt Medica became a fully owned subsidiary of Vygon, supporting the latter’s operations in South America. In September 2021, Abbott introduced plant-based protein and organic food ingredients—PediaSure Harvest and Ensure Harvest—for people relying on feeding tubes. Harvest products can be used as sole-source nutrition or a supplement to satisfy daily nutrition requirements. In December 2020, Abbott launched the Pedialyte Hydration Solution, a new formulation designed with key nutrients to support immune health. Pedialyte with immune support includes prebiotics, vitamin B12, vitamin C, vitamin E, and zinc, specifically chosen for their importance in the development and improvement of the immune system. In October 2020, Nutricia (part of Danone) acquired Real Food Blends. The company helps contribute to the real food blends mission and portfolio by bringing more unique and nutritious choices to children and adults dependent on feeding tubes. Therefore, introducing products such as ready-to-drink and ready-to-use nutritional supplements; the development of innovative products targeting various health issues; and strategic moves such as expansions and acquisitions allow companies in the enteral and parenteral medical nutrition market to create new or improved products and new business to remain competitive in the market. Thus, such strategic growth initiatives create significant growth opportunities in the market.

On the contrary, mechanical, gastrointestinal, and metabolic complications associated with enteral and parenteral feeding systems, and limitations related to catheter placement hampers the South & Central America Enteral and Parenteral Medical Nutrition Market.  

Based on indication, the South & Central America enteral and parenteral medical nutrition market is segmented into elderly, gastrointestinal disorders, diabetes, cancer, respiratory disorders, alzheimer’s disease, dementia, renal disease, liver failure, post covid-19, and other indications. The elderly segment held 29.9% share of South & Central America Enteral and Parenteral Medical Nutrition Market in 2023, amassing US$ 291.65 million. It is projected to garner US$ 415.73 million by 2028 to expand at 7.3% CAGR during 2023–2028.

Based on nutrition type, the South & Central America enteral and parenteral medical nutrition market is segmented into supplemental and sole source. The supplemental segment held 78.9% share of South & Central America Enteral and Parenteral Medical Nutrition Market in 2023, amassing US$ 769.86 million. It is projected to garner US$ 1,079.47 million by 2028 to expand at 7.0% CAGR during 2023–2028.

Based on form, the South & Central America enteral and parenteral medical nutrition market is segmented into liquid, powder, and semi solid. The liquid segment held 53.0% share of South & Central America Enteral and Parenteral Medical Nutrition Market in 2023, amassing US$ 517.55 million. It is projected to garner US$ 725.68 million by 2028 to expand at 7.0% CAGR during 2023–2028.

Based on product type, the South & Central America enteral and parenteral medical nutrition market is segmented into general and disease specific. The general segment held 57.6% share of South & Central America Enteral and Parenteral Medical Nutrition Market in 2023, amassing US$ 562.26 million. It is projected to garner US$ 800.55 million by 2028 to expand at 7.3% CAGR during 2023–2028.

Based on route of administration, the South & Central America enteral and parenteral medical nutrition market is segmented into oral, tube feed, and parenteral. The parenteral segment held 43.9% share of South & Central America Enteral and Parenteral Medical Nutrition Market in 2023, amassing US$ 427.84 million. It is projected to garner US$ 600.11 million by 2028 to expand at 7.0% CAGR during 2023–2028.

Based on age group, the South & Central America enteral and parenteral medical nutrition market is segmented into above 60 years, 18-60 years, 3-18 years, and below 3 years. The above 60 years segment held 39.4% share of South & Central America Enteral and Parenteral Medical Nutrition Market in 2023, amassing US$ 384.08 million. It is projected to garner US$ 544.13 million by 2028 to expand at 7.2% CAGR during 2023–2028.

Based on distribution channel, the South & Central America enteral and parenteral medical nutrition market is segmented into a hospital pharmacies, retail stores, e-commerce, and others. The hospital pharmacies segment held 41.0% share of South & Central America Enteral and Parenteral Medical Nutrition Market in 2023, amassing US$ 399.80 million. It is projected to garner US$ 557.91 million by 2028 to expand at 6.9% CAGR during 2023–2028.

Based on country, the South & Central America enteral and parenteral medical nutrition market has been categorized into Brazil, Argentina, Chile, Peru, Colombia, Mexico, and the Rest of South & Central America. Our regional analysis states that Brazil captured 32.8% share of South & Central America Enteral and Parenteral Medical Nutrition Market in 2023. It was assessed at US$ 320.08 million in 2023 and is likely to hit US$ 460.41 million by 2028, exhibiting a CAGR of 7.5% during the forecast period.      

Key players dominating the South & Central America enteral and parenteral medical nutrition market are Abbott Laboratories; B. Braun SE; Baxter International Inc; Fresenius Kabi AG; Nestle SA; and Nutricia International BV, among others.  

• November 2021, Abbott Launched Similac 360 Total Care to Support the Immune System, Digestive Health and Brain Development. Similac 360 Total Care is the first and only infant formula in the U.S. with a blend of five different HMOs, previously only found together in breast milk. This formula is designed to provide nutrition to support the whole baby’s health and development, including the developing immune system, digestive system and brain.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com